105 related articles for article (PubMed ID: 38477419)
1. The Use of Compounds Derived from
Stasiłowicz-Krzemień A; Nogalska W; Maszewska Z; Maleszka M; Dobroń M; Szary A; Kępa A; Żarowski M; Hojan K; Lukowicz M; Cielecka-Piontek J
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891938
[TBL] [Abstract][Full Text] [Related]
2. Phytocannabinoids in neuromodulation: From omics to epigenetics.
Banerjee S; Saha D; Sharma R; Jaidee W; Puttarak P; Chaiyakunapruk N; Chaoroensup R
J Ethnopharmacol; 2024 Aug; 330():118201. PubMed ID: 38677573
[TBL] [Abstract][Full Text] [Related]
3. Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis.
Notcutt WG
Neurotherapeutics; 2015 Oct; 12(4):769-77. PubMed ID: 26289248
[TBL] [Abstract][Full Text] [Related]
4. Self-reported Cannabidiol (CBD) Use for Conditions With Proven Therapies.
Leas EC; Hendrickson EM; Nobles AL; Todd R; Smith DM; Dredze M; Ayers JW
JAMA Netw Open; 2020 Oct; 3(10):e2020977. PubMed ID: 33057645
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoids: Potential for Modulation and Enhancement When Combined with Vitamin B12 in Case of Neurodegenerative Disorders.
Kaszyńska AA
Pharmaceuticals (Basel); 2024 Jun; 17(6):. PubMed ID: 38931480
[TBL] [Abstract][Full Text] [Related]
6. Cannabis and cancer: unveiling the potential of a green ally in breast, colorectal, and prostate cancer.
ALSalamat HA; Abuarab SF; Salamah HM; Ishqair AH; Dwikat MF; Nourelden AZ; Qandil AN; Barakat Y; Barakat M
J Cannabis Res; 2024 May; 6(1):24. PubMed ID: 38755733
[TBL] [Abstract][Full Text] [Related]
7. Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.
Junior NCF; Dos-Santos-Pereira M; Guimarães FS; Del Bel E
Neurotox Res; 2020 Jan; 37(1):12-29. PubMed ID: 31637586
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective potential of cannabidiol: Molecular mechanisms and clinical implications.
Tambe SM; Mali S; Amin PD; Oliveira M
J Integr Med; 2023 May; 21(3):236-244. PubMed ID: 36973157
[TBL] [Abstract][Full Text] [Related]
9. Source of cannabinoids: what is available, what is used, and where does it come from?
Specchio N; Pietrafusa N; Cross HJ
Epileptic Disord; 2020 Jan; 22(S1):1-9. PubMed ID: 31941643
[TBL] [Abstract][Full Text] [Related]
10. Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease.
Silvestro S; Schepici G; Bramanti P; Mazzon E
Molecules; 2020 Nov; 25(21):. PubMed ID: 33171772
[TBL] [Abstract][Full Text] [Related]
11. Advances and Challenges of Cannabidiol as an Anti-Seizure Strategy: Preclinical Evidence.
Zavala-Tecuapetla C; Luna-Munguia H; López-Meraz ML; Cuellar-Herrera M
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555823
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders.
de Fátima Dos Santos Sampaio M; de Paiva YB; Sampaio TB; Pereira MG; Coimbra NC
Basic Clin Pharmacol Toxicol; 2024 May; 134(5):574-601. PubMed ID: 38477419
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
